Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Vonjo (pacritinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

SOBI

Drug class:

JAK2 inhibitor, FLT3 inhibitor, CSF-1R inhibitor, ACVR1 inhibitor, IRAK-1 inhibitor

Related drugs:

axatilimab-csfr (0)

vimseltinib (0)

entrectinib (178)

ruxolitinib (73)

momelotinib (2)

tofacitinib (1)

FAK-JAK 2 dual Inhib (0)

flonoltinib (0)

BS-HH-002.SA (0)

quizartinib (40)

ripretinib (11)

pexidartinib (6)

avapritinib (13)

axatilimab-csfr (0)

vimseltinib (0)

›

FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	SB939 + pacritinib Sensitive: D – Preclinical SB939 + pacritinib Sensitive : D	SB939 + pacritinib Sensitive: D – Preclinical SB939 + pacritinib Sensitive : D
JAK2 V617F	Acute Myelogenous Leukemia	JAK2 V617F	Acute Myelogenous Leukemia	SB939 + pacritinib Sensitive: D – Preclinical SB939 + pacritinib Sensitive : D	SB939 + pacritinib Sensitive: D – Preclinical SB939 + pacritinib Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	pacritinib Sensitive: D – Preclinical pacritinib Sensitive : D	pacritinib Sensitive: D – Preclinical pacritinib Sensitive : D